How to Bridge with Rivaroxaban
Bridging anticoagulation is NOT recommended when using rivaroxaban – unlike warfarin, rivaroxaban's rapid onset and offset of action (half-life 10-14 hours) eliminates the need for heparin bridging during transitions or perioperative interruptions 1, 2.
Switching FROM Warfarin TO Rivaroxaban
Stop warfarin and start rivaroxaban when INR drops below 3.0 (adults) or below 2.5 (pediatric patients) 3. This approach avoids periods of inadequate anticoagulation while preventing excessive anticoagulant effect from overlapping therapies.
Key Implementation Points:
- No heparin bridging is required during this transition 3
- Monitor INR before starting rivaroxaban to confirm it's in the safe range
- Begin rivaroxaban at standard dosing once INR criteria are met
- The synergistic effect of residual warfarin plus rivaroxaban is strongest in the first 2-3 days, then becomes additive 4
Switching FROM Rivaroxaban TO Warfarin
Continue rivaroxaban for at least 2 days after starting warfarin (pediatric patients), or use a parenteral anticoagulant bridge (adults) 3.
For Pediatric Patients:
- Start warfarin while continuing rivaroxaban
- After 2 days of co-administration, check INR before the next rivaroxaban dose
- Continue both drugs until INR ≥2.0
- Once rivaroxaban is stopped, wait 24 hours before checking INR for warfarin monitoring 3
For Adults:
- Discontinue rivaroxaban
- Start both a parenteral anticoagulant (LMWH or UFH) AND warfarin at the time of the next scheduled rivaroxaban dose
- Continue parenteral anticoagulant until INR is therapeutic 3
- Important caveat: Rivaroxaban affects INR measurements, making them unreliable for warfarin dosing during overlap 3
Perioperative Management (NO Bridging Required)
Stop rivaroxaban 1-2 days before low-to-moderate bleeding risk procedures, or 2 days before high bleeding risk procedures 2.
Pre-Procedure Interruption:
- Low-to-moderate bleeding risk: Hold rivaroxaban for 1 day (24 hours) 2
- High bleeding risk: Hold rivaroxaban for 2 days (48 hours) 2
- No heparin bridging should be used during this interruption 1, 2
Post-Procedure Resumption:
- Low-to-moderate bleeding risk: Resume rivaroxaban approximately 24 hours after procedure once hemostasis is established 2
- High bleeding risk: Resume rivaroxaban 48-72 hours after procedure 2
- In selected high VTE risk patients, prophylactic-dose LMWH (enoxaparin 40 mg daily or dalteparin 5,000 IU daily) may be given for the first 48-72 hours post-procedure before resuming full-dose rivaroxaban 2
Evidence Supporting No Bridging
The PAUSE study (3,007 patients) demonstrated that rivaroxaban interruption without bridging resulted in low rates of major bleeding (1.85%) and stroke/systemic embolism (0.37%) 1. Multiple studies consistently show that heparin bridging with DOACs like rivaroxaban increases major bleeding risk 3-4 fold (OR 4.6) without reducing thrombotic events 2.
The Dresden Registry found that bridging with rivaroxaban led to significantly higher major bleeding (2.7% vs 0.5%, P=0.010) without reducing cardiovascular events 1.
Common Pitfalls to Avoid
- Never use heparin bridging when interrupting rivaroxaban – this is the most critical error, as it dramatically increases bleeding risk without benefit
- Don't rely on INR for monitoring during warfarin-to-rivaroxaban transitions, as rivaroxaban affects INR values
- Don't restart rivaroxaban too early after high-bleeding-risk procedures – wait for adequate hemostasis (48-72 hours)
- Avoid bridging in atrial fibrillation patients even with high CHADS₂ scores, mechanical valves being the main exception where warfarin remains preferred 1
Special Populations
Renal impairment: Adjust pre-procedure interruption timing based on creatinine clearance, though specific rivaroxaban guidance is limited in advanced CKD 2. Recent evidence suggests apixaban may have superior safety in CKD stage 4/5 compared to rivaroxaban 5.
Pediatric patients: Use weight-based dosing tables and adjust interruption timing for shorter half-life in younger patients 6. Periprocedural management extrapolated from adult PAUSE study: pause 24 hours before low-risk procedures, 48 hours before high-risk procedures 6.